DATE: July 5, 2022

TO: All Prescription Drug Plans, Medicare Advantage-Prescription Drug Plans, Section 1876 Cost Plans, Medicare-Medicaid Plans, and PACE plans

FROM: Amy Larrick Chavez-Valdez
Director, Medicare Drug Benefit and C & D Data Group

SUBJECT: Contract Year (CY) 2023 Opioid Safety Edits – Submission Instructions

This memorandum provides instructions to Part D sponsors for submitting information about CY 2023 opioid point-of-sale (POS) safety edit(s) to CMS in the Health Plan Management System (HPMS).

Background

Medicare Part D sponsors must have concurrent drug utilization review (DUR) systems, policies, and procedures designed to ensure that a review of the prescribed drug therapy is performed before each prescription is dispensed to an enrollee in a sponsor’s Part D plan, typically at the POS or point of distribution as described in 42 CFR § 423.153(c)(2). To help prevent and combat prescription opioid overuse through improved concurrent DUR, sponsors are expected to implement opioid safety edits at the POS, including a care coordination edit based on a cumulative morphine milligram equivalent (MME) threshold of 90 MME per day, a hard safety edit to limit initial opioid prescription fills for the treatment of acute pain to no more than a 7 day supply, and an optional hard MME edit.1

Updates to the Submission Process

For CY 2023, Part D sponsors should submit opioid safety edit information in the Opioid Safety Edits module in HPMS. Authorized HPMS users may locate the module under Plan Formularies → Opioid Safety Edits. The Plan User Guide for CY 2023, with detailed instructions on how to submit and revise opioid safety edits, is in the module under Documentation.

Sponsors should submit opioid safety edits in the HPMS module between **August 15, 2022 and 5:00 p.m. EDT on August 22, 2022**. As a reminder, PACE organizations only need to submit opioid safety edit information if adjudicating claims at POS.

Using the module, sponsors should provide information on: the opioid care coordination edit, such as whether the sponsor will include an opioid prescriber and/or pharmacy count, and the number of prescribers and/or pharmacies; an MME hard edit (if applicable); and the opioid naïve 7 day supply edit. Please note that the submission of the opioid safety edit information aids in CMS’ monitoring and does not represent approval or denial of a sponsor’s opioid safety edits.

If a sponsor wishes to revise their CY 2023 opioid safety edits after the initial submission window, they may do so by sending an email to PartD_OM@cms.hhs.gov with the subject line “Opioid Safety Edit Request to Revise – [applicable contract ID number(s)].” The email should include:

1. The contract ID(s) associated with this change;
2. The intended revisions to the opioid safety edit(s);
3. The proposed implementation date of the revision; and
4. A justification for the mid-year change to the opioid safety edit(s).

If the justification and revisions are accepted, CMS will notify the sponsor to allow edits in the HPMS Opioid Safety module.

For questions related to this memorandum or for assistance completing the initial submission, email PartD_OM@cms.hhs.gov.